Health 2.0 Europe 2011

27 - 28 October 2011, Berlin, Germany.
Following the success of the first edition in Paris in April 2010, the 2nd annual Health 2.0 Europe in Berlin has been announced. The 2010 event gathered over 500 delegates in its first year and showcased the best of Europe's Health 2.0 offerings with some American input too. Co-hosted with K.I.T. Group, the 2nd edition will reconvene all the leaders and stakeholders in web 2.0 health: IT solution providers, health professionals, patient organizations, health authorities, public and private insurance organizations, medical devices and pharmaceutical companies, telecom groups, VC and financiers, policy makers, academics and more...

2011 Program Highlights
Health 2.0 Europe integrates the best of European web/mobile based technologies, and compares, contrasts and contextualizes them with leading examples of Health 2.0 from around the world. Health 2.0 Europe will be seeing what works in the context of Europe's evolving healthcare systems, and what the "boundary-less" online world means for consumers and physicians working in distinct healthcare systems - all in the lauded format of "rapid-fire" technology demos, provocative keynotes, and interactive discussions. 2011 themes will include:

  • Patient and physician social networks
  • Search & content
  • Communities and data production
  • Consumer and provider tools
  • Health promotion and wellness 2.0
  • Behavior change tools
  • Privacy, data, trust
  • Data utility layer & tools
  • System integration
  • Health 2.0 financing
  • Mobile devices and smart phones

There'll also be a presentation of the latest thinking about Health 2.0 in the European context, special videos, and an unconference session.

A signature of the Health 2.0 conferences, Launch!, will be back by popular demand. Come witness live demos of debuting technologies that will shape the future of healthcare.

Make it your event. Get involved now!
To submit a topic, a speaker, or a start up for the Launch! session, or to inquire about becoming a partner of the event, please contact:

Pascal Lardier, Director, International conferences
This email address is being protected from spambots. You need JavaScript enabled to view it.

Historical Venue
After the Cité Internationale in April 2010, the 2011 event is taking us to yet another historical landmark: the Langenbeck-Virchow building of the Charité Hospital and University of Medicine.

It was built in 1914-15 to be the seat of the German Surgical Society and the Berlin Medical Association. From 1950 to 1976, the Parliament of East Germany was constituted in its auditorium and started convening in the Great Hall. After the collapse of Berlin Wall in 1989 and a long legal conflict, the German Surgical Society and the Berlin Medical Association returned to their home.

For further information and registration, please visit:
http://www.health2con.com/europe/

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

Pfizer receives FDA approval for SUTENT® (sunitini…

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration has approved a new indication expanding the use of SUTENT® (sunitinib malate) to include...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

New US study reveals key reasons why millions of p…

Few of the more than 90 million Americans(1) with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment I...

Efficacy and safety maintained in patients who swi…

Boehringer Ingelheim today announced one-year data from VOLTAIRE®-RA, a pivotal Phase III clinical trial comparing Cyltezo® (adalimumab-adbm) and reference product Humira...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]